Results 31 to 40 of about 12,412 (210)

Secukinumab Efficacy in Psoriatic Arthritis : Machine Learning and Meta-analysis of Four Phase 3 Trials

, 2020
International audienceBackground: Using a machine learning approach, the study investigated if specific baseline characteristics could predict which psoriatic arthritis (PsA) patients may gain additional benefit from a starting dose of secukinumab 300 mg
Pricop, Luminita, Kirkham, Bruce, Bruce Kirkham, Balsa, Alejandro, Gottlieb, Alice B, Alice B. Gottlieb, Gregory Ligozio, Abrams, Ken, Luminita Pricop, Ken Abrams, Xuan Zhu, Rech, Jürgen, David James, Peter Nash, Gottlieb, Alice B., Mease, Philip, Combe, Bernard, Zhu, Xuan, Ruvie Martin, Jürgen Rech, Mease, Philip J., Philip J. Mease, Alejandro C. Balsa, Ligozio, Gregory, Mease, Philip J, Nash, Peter, Gottlieb, Alice, Balsa, Alejandro C, Martin, Ruvie, James, David, Balsa, Alejandro C., Bernard Combe   +31 more
core   +1 more source

Secukinumab-induced pompholyx in a psoriasis patient [PDF]

, 2020
With a prevalence of up to 20%, eczematous lesions are the most common skin adverse events of tumor necrosis factor alpha inhibitors. Eczematous lesions triggered by more modern biologics such as the IL17A antagonist secukinumab have been rarely reported.
Eichhoff, Gerhard
core   +1 more source

Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials

, 2017
BACKGROUND Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis.
蔡呈芳, Langley, Richard G.;Elewski, Boni E.;Lebwohl, Mark;Reich, Kristian;Griffiths, Christopher E. M.;Papp, Kim;Puig, Lluis;Nakagawa, Hidemi;Spelman, Lynda;Sigurgeirsson, Bardur;Rivas, Enrique;Tsai, Tsen-Fang;Wasel, Norman;Tyring, Stephen;Salko, Thomas;Hampele, Isabelle;Notter, Marianne;Karpov, Alexander;Helou, Silvia;Papavassilis, Charis   +1 more
core   +2 more sources

A review of secukinumab in psoriasis treatment

, 2021
Psoriasis is a systemic immunologic disorder associated with decreased quality of life and numerous co-morbidities, including psoriatic arthritis and cardiovascular disease.
Ghamrawi, Rima I., Feldman, Steven R., Balogh, Esther A., Berg, Scott H.   +3 more
core   +1 more source

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study

Arthritis Research & Therapy, 2018
Background Pain is one of the most important domains affecting health-related quality of life (HRQoL) in patients with psoriatic arthritis (PsA). Secukinumab has demonstrated rapid and sustained improvements in signs and symptoms, including HRQoL, among ...
Iain B. McInnes, Philip J. Mease, Georg Schett, Bruce Kirkham, Vibeke Strand, Nicole Williams, Todd Fox, Luminita Pricop, Steffen M. Jugl, Kunal K. Gandhi, on behalf of the FUTURE 2 Study Group   +10 more
doaj   +1 more source

Treatment response in patients with moderate-to-severe psoriasis who had inadequate response to prior secukinumab

Dermatologica Sinica, 2019
Background/Objective: Secukinumab is an effective treatment for psoriasis, and it has been reported to be effective in patients who failed on multiple prior biologics.
Tai-Siang Chiu, Tsen-Fang Tsai
doaj   +1 more source

Management of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs

Вопросы современной педиатрии, 2021
The article shows the key role of IL-17 in the psoriasis pathogenesis and the opportunities of its management via monoclonal antibodies product secukinumab.
Leyla S. Namazova-Baranova, Andrey L. Bakulev, Nikolay N. Murachkin, Lyudmila N. Nam, Roman A. Ivanov   +4 more
doaj   +1 more source

From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis

Arthritis Care &Research, EarlyView.
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases encompassing axial and peripheral forms, with up to 20% of patients developing symptoms before age 16. Despite this substantial pediatric burden, treatment options for juvenile‐onset SpA (JSpA), particularly those with axial disease (axJSpA), remain limited.
Pamela F. Weiss, Judith A. Smith, Robert A. Colbert, Erin Treemarcki, Michael H. Weisman, Walter P. Maksymowych, Hermine I. Brunner, for the Childhood Arthritis and Rheumatology Research Alliance, Spondyloarthritis Research and Treatment Network, and Pediatric Rheumatology Collaborative Study Group Advisory Council   +9 more
wiley   +1 more source

Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report

, 2023
Xujun Lu, Wenge Wang Department of Pediatrics, Air Force Medical Center, Air Force Medical University, PLA, Beijing, 100142 People’s Republic of ChinaCorrespondence: Wenge Wang, Department of Pediatrics, Air Force Medical Center, Air Force Medical ...
Lu X, Wang W
core  

Secukinumab for psoriatic arthritis:comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis [PDF]

, 2018
Aim: A network meta-analysis (NMA) using randomized controlled trial data compared psoriatic arthritis (PsA) outcomes (ACR, PASI and PsARC response rates) at 12–16 weeks for secukinumab, adalimumab, apremilast, certolizumab, etanercept, golimumab ...
Choy, Ernest, Gandhi, Kunal, Pricop, Luminita, Kantars, Steve, Ghandhi, Kunal, Choy, Ernest H., Nash, Peter, Jugl, Steffen M, Ritchlin, Christopher, Kanters, Steve, McInnes, Iain B, Thom, Howard, Choy, Ernest H, McInnes, Iain B., Jugl, Steffen M.   +14 more
core   +1 more source